Trial Profile
An Open-Label, Multicenter, Phase I Dose-Escalation Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vofatamab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 23 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 May 2012 Actual number of patients changed from 50 to 23, as reported by ClinicalTrials.gov.
- 23 May 2012 Actual initiation date changed from Aug 2011 to Jul 2011, as reported by ClinicalTrials.gov.